Highlights

  • ReNerve will hold a quarterly report webinar at 11am AEDT on Monday, 2 November 2026.
  • CEO and Managing Director Dr Julian Chick will present an update, including the Appendix 4C.
  • FY25 revenue grew 53% to A$271,000, with further sales growth reported year to date in FY2026.
  • The global nerve repair market is projected to grow from US$1.6 billion in 2024 to US$6.2 billion by 2031.

ReNerve Limited (ASX:RNV), an Australian biotechnology company focused on peripheral nerve injury repair, has announced that it will host a webinar to discuss its quarterly report. The session will give investors an update on recent activities, including the company's Appendix 4C quarterly cash flow report.

Webinar Details

The webinar will take place at 11am AEDT on Monday, 2 November 2026, and will be hosted by Dr Julian Chick, Chief Executive Officer and Managing Director. Registration is available through the company's Zoom link, and a replay will be available at the same link after the event.

Investors can submit questions on the day or in advance through NWR Communications, which manages ReNerve's investor and media relations.

Product Portfolio and Pipeline

ReNerve was founded by a neurosurgeon and medtech researchers. Its marketed products include the FDA-cleared NervAlign Nerve Cuff, a bioabsorbable protective wrap that is naturally absorbed within six months of surgery, as well as the Empliq Deep Dermal tissue product and three Empliq Amniotic tissue product ranges used in wound healing.

The development pipeline includes the NervAlign Nerve Conduit Range for short nerve gaps, the NervAlign Nerve Guide Matrix for longer gaps as an alternative to nerve grafts, and the NervAlign Bionic Nerve for the most challenging repairs.

Clinical Results and Sales Growth

According to the company, patients treated with the NervAlign Nerve Cuff saw post-surgical pain scores fall from 7.1 to 0.4, compared with a reduction from 7.1 to 3.3 for patients without the device. ReNerve describes this difference as statistically significant.

Since launching its products in 2022, ReNerve grew FY25 revenue by 53% to A$271,000 and reports further significant sales increases across its portfolio in FY2026 to date. The company cites a global nerve repair market valued at US$1.6 billion in 2024, projected to reach US$6.2 billion by 2031.

Key Takeaways

  • ReNerve's quarterly webinar on 2 November 2026 will cover recent activities and the Appendix 4C.
  • The company has a mix of marketed nerve and tissue repair products and a development pipeline.
  • Sales have been growing since launch, in a nerve repair market projected to expand significantly.